Navigation Links
Clinical ovarian cancers display extensive genetic heterogeneity, study suggests multiple treatment
Date:11/14/2013

CARLSBAD, Calif. and UTRECHT, The Netherlands Nov. 12, 2013 One of the most comprehensive studies of genetic mutations in ovarian cancer was published today, demonstrating an unprecedented level of genetic variation that exists in both primary tumors and metastatic lesions of ovarian cancer. The study highlights potential new pathways for therapeutic intervention and suggests that sampling and sequencing of multiple disease sites may be required for effective targeted treatments.

The paper, titled "Genomic and transcriptomic plasticity in treatment-nave ovarian cancer," is available online at the journal Genome Research and is authored by scientists at the University Medical Center Utrecht in The Netherlands and Life Technologies Corporation in Carlsbad, Calif. With an annual global incidence of 220,000 and mortality of 140,0001, ovarian cancer is a leading cause of cancer deaths in women, making it a disease in urgent need of improved treatment.

The researchers examined a total of 27 archived tumor biopsy samples, both from primary tumors as well as distant metastatic sites, gathered from three women with late stage (IIIC/IV) ovarian cancer. Tumor samples and matched normal tissue samples were analyzed using a variety of methods, including transcriptome and mate-pair sequencing and several targeted gene sequencing panels. Sequencing was conducted on the Applied Biosystems SOLiD 5500xL and Ion Personal Genome Machine (PGM), both from Life Technologies, using Life's Ion AmpliSeq Comprehensive Cancer Panel, a panel of more than 400 genes that have been implicated in cancer. This study represents the first peer-reviewed, scientific publication employing this panel of 409 oncogenes.

The sequencing data revealed a striking degree of genetic heterogeneity within each individual's cancer. This was evident from profiles of coding mutations, genomic structural variation and gene expression changes. Of note, one of the individuals displayed
'/>"/>

Contact: Suzanne Clancy
Suzanne.Clancy@lifetech.com
760-602-4545
Life Technologies
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Elseviers Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical
2. Baxter Completes Enrollment In Phase III Clinical Trial Of BAX 855, Extended Half-life Recombinant FVIII For Hemophilia A
3. Development and clinical approval of biodegradeble magnesium alloy
4. Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing
5. KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH
6. Breastfeeding as a possible deterrent to autism -- a clinical perspective
7. Projecis Cloud-based Collaboration Platform Selected by Spaulding Clinical to Manage Phase I Clinical Trial Projects and Timelines
8. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
9. Picofemto Deploys Cloud-Based Cliniscan EEG Analytics and Clinical Decision Support
10. UNLV, Sen. Reid Announce $20 Million NIH grant to support clinical health research
11. Wistar receives $1.5 million Department of Defense grant to ready prostate drug for clinical use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 4, 2010 -- Supercomputer simulations at the Department of Energy,s ... acids could have contributed to the origins of life. ... directs ORNL,s Center for Molecular Biophysics and holds a Governor,s ... probe an organic chemical reaction that may have been important ...
... Rockville, MD, USA (October 4, 2010) The ... receipt of a grant from the United States Food ... immunological biomarkers for TB vaccine development. The FDA grant, ... researchers from the United States, the United Kingdom and ...
... Ben Major, PhD, assistant professor of cell and developmental ... of Health Director,s New Innovator Awards, one of the ... will fund his work to address a significant medical ... functionally contribute to specific cellular and disease processes such ...
Cached Biology News:Powerful supercomputer peers into the origin of life 2Aeras-led research consortium receives FDA support 2UNC scientist receives NIH director's New Innovator Award 2
(Date:11/26/2014)... 25, 2014 Silicon Valley Electronic Data ... RPM Alliance , provider of clinical research and ... the latest addition to its CRO Partnership Program, Clinovo ... system to India. , “We have found Clinovo’s ... customizable EDC platform which is both user friendly and ...
(Date:11/26/2014)... SoundConnect , an award winning unified ... that Darren Suders has joined the team as Director ... the partner program through innovative offerings, consistent ... Darren brings more than 10-years of channel telecommunication experience ... operations, from policy development, to partner education and to ...
(Date:11/26/2014)... , 25 novembre 2014 /PRNewswrie/ -- Theravalues Corporation ... il mercato europeo in occasione di Hi Europe 2014 ... ). Si tratta della curcumina con la ... amorfa (senza cristalli) e ingredienti approvati dalle norme europee. ... nella spezia della pianta curcumina ( Curcuma longa ) ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... diagnostic tests for cancer and other conditions, today announced that ... at the Science for Business BioWin Day 2014, being held ... The data come from VolitionRx,s lung cancer pilot study, the ... the Centre Hospitalier Universitaire (CHU) de Liege in ...
Breaking Biology Technology:RPM Alliance Joins Clinovo’s CRO Partnership Program, Further Strengthening Its Presence in Southern California and India 2SoundConnect Appoints Director of Channel Development & Sales 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... 2010 ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { ...
... Inc. (OTC Bulletin Board: CSBR ), a ... and tumor specific data to enhance the value of ... joined the management team as the Chief Executive Officer ... Dr. Ronnie Morris will join the management team as ...
... Oct. 28 Q3 2010 Change on a reported ... 9 months 2010Change on a reported ... sales , €7,821m+5.7% , -1.7% , €22,989m+4.8% , ... €7,377m+8.7% , +6.0%Business EPS(1)€1.89+8.6%-2.3%€5.65+8.7%+6.0% In order to facilitate an understanding ...
Cached Biology Technology:Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 2Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 3Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 4Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 5Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 6Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 7Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 8Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 9Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 10Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 11Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 12Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 13Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 14Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 15Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 16Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 17Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 18Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 19Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 20Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 21Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 22Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 23Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 24Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 25Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 26Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 27Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 28Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 29Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 30Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 31Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 32Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging 33Champions Biotechnology Reports Additions to its Management Team 2Champions Biotechnology Reports Additions to its Management Team 3Champions Biotechnology Reports Additions to its Management Team 4
... to the Salmonella Common Structural Antigens (CSA) ... serum pool of goats immunized with different ... broadly reactive to Salmonella and recognizes all ... excellent specificity for Group B and D ...
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... products into 1:, , A multi-tube homogenizer ... , ,The FastPrep System consists of ... Matrix and Isolation Kits. Samples are homogenized ... the use of metal probes and shearing ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: